

✓
Kindly insert the paper copy of the sequence listing provided herewith as pages 56-87 into the specification. Kindly renumber the pages of claims beginning at page 88.

IN THE CLAIMS

Kindly cancel claims 23, 53, and 58

Kindly amend the following claims:

A2

3. (Amended) A nucleic acid molecule according to claim 1 wherein said nucleic acid is a cDNA molecule.

A3

5. (Amended) An antisense molecule capable of hybridising to a molecule according to claim 1 under high stringency conditions.

6. (Amended) A nucleic acid molecule according to claim 1 which is of mammalian origin.

A4

9. (Amended) A VEGF-X protein, or a functional equivalent, derivative or bioprecursor thereof, encoded by a nucleic acid molecule as defined in claim 1.

10. (Amended) A VEGF-X protein comprising the amino acid sequence illustrated in Figure 10.

11. (Amended) An expression vector comprising a nucleic acid molecule according to claim 1.

A5

14. (Amended) A pharmaceutical composition comprising a nucleic acid molecule according to claim 1 or an antisense molecule according to claim 5.

15. (Amended) A host cell transformed or transfected with an expression vector according to claim 11.

A6
17. (Amended) A transgenic cell, tissue or organism comprising a transgene capable of expressing a VEGF-X protein according to claim 8.

A7
21. (Amended) A process for producing a VEGF-X protein according to claim 8, said process comprising transforming a host cell or organism with an expression vector according to claim 11, and recovering the expressed protein from said host cell or organism.

22. (Amended) An antibody capable of binding to a protein according to claim 8, or an epitope thereof.

A8
26. (Amended) A kit for identifying the presence of VEGF-X protein in a sample which comprises an antibody according to claim 22.

A9
29. (Amended) A pharmaceutical composition comprising a compound according to claim 28 for use as a medicament.

30. (Amended) A nucleic acid sequence selected from the group consisting of the nucleotide sequences illustrated in any of Figures selected from the group of Figures comprising Figures 3, 5, 8 and 13.

A10
41. (Amended) A nucleic acid molecule according to claim 39, comprising the nucleotide sequence from position 5 to 508 of the sequence illustrated in Figure 26.

42. (Amended) A nucleic acid molecule according to claim 39 comprising the nucleotide sequence illustrated in Figure 26.

A11

44. (Amended) An expression vector comprising a nucleic acid molecule according to claim 39.

A12

52. (Amended) A method of inhibiting angiogenic activity or inappropriate vascularisation, said method comprising contacting a cell expressing a VEGF receptor and a neuropilin type receptor with a protein selected from the group of a protein according to claim 8, a protein according to claim 48, and a protein according to claim 49.

A13

55. (Amended) A nucleic acid molecule according to claim 54 wherein said sequence encoding said VEGF domain is selected from the sequences encoding any of VEGF A to D.

56. (Amended) A pharmaceutical composition comprising a nucleic acid molecule encoding a polypeptide, the polypeptide having an amino acid sequence comprising the amino acid sequence from position 40 to 150 of the sequence illustrated in Figure 10.

57. (Amended) A method for treating a disease condition associated with inappropriate angiogenesis including tumour or cancer growth, retinopathy, osteoarthritis or psoriasis in a patient comprising contacting the patient with a pharmaceutical composition comprising a nucleic acid molecule encoding a polypeptide having the amino acid sequence from position 40 to 150 of the sequence illustrated in Figure 10.

A14

59. (Amended) A method for treating a disease conditions associated with inappropriate angiogenesis such as tumour growth, retinopathy, osteoarthritis or

psoriasis comprising contacting the patient with a polypeptide comprising the amino acid sequence from position 40 to 150 of the sequence illustrated in Figure 10.

60. Use of a CUB domain comprising the amino acid sequence from position 40 to 150 of the sequence of Figure 10, or the amino acid sequence of Figure 26, to identify compounds which inhibit angiogenic activity in a method according to claim 50.

61. (Amended) A method of inhibiting angiogenic activity and inappropriate vascularisation including formation and proliferation of new blood vessels, growth and development of tissues, tissue regeneration and organ and tissue repair in a subject said method comprising administering to said subject an amount of a polypeptide having an amino acid sequence from position 40 to 150 of the sequence illustrated in Figure 10 or a nucleic acid molecule according to claim 39 in sufficient concentration to reduce or prevent said angiogenic activity.

62. (Amended) A method of treating or preventing any of cancer, rheumatoid arthritis, psoriasis and diabetic retinopathy, said method comprising administering to said subject an amount of a polypeptide having an amino acid sequence from position 40 to 150 of the sequence illustrated in Figure 10 or a nucleic acid molecule according to claim 39 in sufficient concentration to treat or prevent said disorders.

63. (Amended) An antisense molecule capable of hybridising to a molecule according to claim 39 under high stringency conditions.